Design and Evaluation of Chronomodulated Drug Delivery of Tramadol Hydrochloride

Abstract

Rheumatoid arthritis is an auto immune disease which requires chronotherapy as it occurs during early morning. Tramadol hydrochloride (TH) is an analgesic drug, used to treat rheumatoid arthritis. The aim of the present investigation was to develop chronomodulated drug delivery system of tramadol hydrochloride such that it releases the drug early in the morning, during which the symptoms of rheumatoid arthritis worsen. To develop chronomodulated drug delivery system of TH, initially core tablets of TH were prepared using three different supradisintegrants followed by coating with pH dependent polymer of Eudragit S100. The prepared core tablets are evaluated for physical parameters and an optimal system was identified. Further, coating composition of Eudragit S100 was optimized and coating tablets of TH was prepared. The prepared coated tablets were evaluated for weight variation, hardness, drug content and in vitro release studies in 0.1N HCl, pH 6.8 phosphate buffer and pH 7.4 phosphate buffer. Formulation with 7.5% of coating solution (ES2) had shown a significant drug release after a lag time of 3 h (in pH 6.8 medium), 6 h (in pH 6.8 medium) and 8 h (in pH 7.4 medium), respectively. DSC studies revealed that no interaction between core and coated materials with drug was observed. Thus, chronomodulated drug delivery system of TH was formulated and assuming that if a tablet is administered around 9 pm to 10 pm, the drug release starts after a lag time of 6 h i. e., around 3am to 4 am.

Key words

Tramadol hydrochloride - chronotherapy - core tablets - coating tablets - dissolution

• References

• 1 Moore-Ede M, Sulzman MC, Fuller CA. The Clocks That Time Us, Physiology of the Circadian Timing System. Cambridge, MA: Harvard University Press; 1982: 464
• 2 Moore-Ede M, Fuller C, Sulzman F. The clocks that time us. Harvard University Press; Boston, MA: 1983
• 3 Brock MA. Chronobiology and aging. J Am Geriutr Soc 1982; 39: 74-79
• 4 Lemmer B. Circadian rhythms and drug delivery. J Contr rel 1991; 16: 63-74
• 5 Bussemer T, Otto I. Bodmeier Pulsatile Drug delivery systems Crit Rev Ther Drug. Carrier syst 2001; 18: 433-458
• 6 Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev 2002; 54: 53-77
• 7 Shidhaye SS, Lotlikar VM, Ghule AM. et al. Pulsatile drug delivery systems: an approach for chronotherapeutic diseases. Sys Rev Pharma 2010; 1: 55-61
• 8 Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmac reports 2009; 61: 978-992
• 9 Ross AC, MacRae RJ, Walther M. et al. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol 2000; 52: 903-909
• 10 Narendar Reddy D, Chinna Reddy P, Sunil R. et al. Development of floating matrix tablets of Ofloxacin and Ornidazole in combined dosage form: in vitro and in vivo evaluation in healthy human volunteers. Int J Drug Del 2012; 4: 462-469
• 11 Küçük A, Kadioğlu Y. Determination of tramadol hydrochloride in ampoule dosage forms by using UV spectrophotometric and HPLC-DAD methods in methanol and water media. Farmaco 2000; 60: 163-169
• 12 Kadam VD, Gattani SG. Formulation and evaluation of a pulsatile drug delivery system using time- and pH-dependant polymers. Pharm Dev Technol 2010; 15: 57-63
• 13 Doodipala N, Palem RC, Reddy S. et al. Pharmaceutical development and clinical pharmacokinetic evaluation of gastro retentive floating matrix tablets of levofloxacin. Int J Pharm Sci Nanotech 2011; 4: 1463-1469
• 14 Hadi MA, Babu VL, Pal N. Formulation and evaluation of sustained release matrix tablets of glimepiride based on combination of hydrophilic and hydrophobic polymers. J Appl Pharm Sci 2012; 2: 101-107